Orthopedic digital x-ray firm EOS Imaging has received clearance from the U.S. Food and Drug Administration (FDA) for its hipEOS 3D hip arthroplasty planning software.
The software is based on EOS stereoradiographic 2D/3D imaging, according to the company. Developed by OneFit Medical, hipEOS allows surgeons to perform presurgical planning including hip implant selection and virtual positioning.
The software uses real-size 3D patient anatomical information obtained from the EOS exam to help physicians define implant size and preoperatively visualize the restoration expected from a total hip arthroplasty, the firm said.
EOS will officially launch hipEOS in the U.S. at the American Academy of Orthopedic Surgeons (AAOS) annual meeting, being held March 24-28, 2015, in Las Vegas.
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
